Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDP-122 · 2 trials · 1 indication
Treatment success defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to "clear" or "almost clear" at Week 8. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe). The face, scalp, palms, soles, axillae, and intertriginous areas were excluded from this assessment.
| Arm | Type | Description |
|---|---|---|
| IDP-122 Lotion | EXPERIMENTAL | Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks. |
| IDP-122 Vehicle Lotion | ACTIVE_COMPARATOR | Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks. |
| Name | Type | Description |
|---|---|---|
| IDP-122 Lotion | DRUG | Topical lotion |
| IDP-122 Vehicle Lotion | DRUG | Topical lotion. No active ingredient. |
Key Inclusion Criteria: * Male or female, of any race, at least 18 years of age (inclusive). * Freely provides both verbal and written informed consent. * Has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (BSA) of at least 3%, but no more than 12%. Th...
IDP-122 is an investigational small molecule being developed for the treatment of plaque psoriasis, a chronic skin condition characterized by red, scaly patches. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
IDP-122 is being developed by Bausch Health Companies Inc., a company publicly traded under the ticker symbol BHC. The drug is in Phase 3 clinical trials for plaque psoriasis.
IDP-122 is in Phase 3 clinical development for plaque psoriasis. It is an investigational drug and has not yet received regulatory approval. Two Phase 3 trials have been completed, each enrolling over 200 participants.
IDP-122 has been studied in two completed Phase 3 clinical trials: NCT02514577, which enrolled 217 participants, and NCT02515097, which enrolled 213 participants. Both trials were randomized, double-blind, placebo-controlled studies conducted in the United States in adults aged 18 years and older with plaque psoriasis.
IDP-122 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for plaque psoriasis. The two Phase 3 trials have been completed, but the drug has not yet received marketing authorization.